<DOC>
	<DOCNO>NCT00504582</DOCNO>
	<brief_summary>Primary Objective : - To determine whether use fibrin sealant apply axillary soft tissue follow node dissection result earlier drain removal . Secondary Objectives : - To determine postoperative morbidity rate use fibrin sealant follow axillary node dissection . - To assess patient-valuation outcome perform cost-benefit analysis use willingness-to-pay model . - To determine serum level , lymphatic fluid level , cutaneous expression vascular endothelial growth factor-D ( VEGF-D ) , vascular endothelial growth factor-C ( VEGF-C ) receptor , vascular endothelial growth factor receptor-3 ( VEGFR-3 ) correlate nodal tumor burden development lymphedema patient melanoma .</brief_summary>
	<brief_title>Fibrin Melanoma Axillary Node Study Patients With Melanoma</brief_title>
	<detailed_description>Patients study schedule axillary node dissection part surgery treatment melanoma . Within 2 week entry study , patient complete physical exam medical history . These patient randomly assign ( toss coin ) one two group . Patients one group receive TISSEEL apply externally dissect axillary area . Patients group receive fibrin sealant . For patient admitted hospital , surgical site monitor surgeon evidence wound complication first 24 hour surgery . At time discharge hospital , patient instruct drain care measure drainage day drain remove . The content drain collected patient first day surgery , first return follow-up visit M.D . Anderson Cancer Center , drain removal ( unless latter 2 date ) . Follow-up wound exam perform local primary physician M.D . Anderson Melanoma Clinic 1-4 week 6 week surgery . Participation 6-week follow-up . THIS IS AN INVESTIGATIONAL STUDY . The sealant FDA approve , though use study experimental . About 115 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Fibrin Tissue Adhesive</mesh_term>
	<criteria>1 . Part I Inclusion Criteria , patient consent participate . 2 . Patients melanoma undergone axillary dissection within last six month part surgical treatment consider study . 1 . Part II Exclusion Criteria , patient know hypersensitivity bovine protein . 2 . Patient undergone prior radiation therapy operative site . 3 . Patient pregnant lactating . 4 . Patient steroid dependent within prior 6 month . 5 . Patient use aspirin antiplatelet drug ( exclude Celebrex ) within seven day operation . 6 . Patient preexist lymphedema . 7 . Patient preexist medical condition evidence organ dysfunction determine principal investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Axillary Node Dissection</keyword>
	<keyword>Fibrin Sealant</keyword>
	<keyword>Tisseel</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Seroma</keyword>
</DOC>